4-Aminopyridine ameliorates experimental autoimmune neuritis in Lewis rats

J Neuroimmunol. 2017 Apr 15:305:72-74. doi: 10.1016/j.jneuroim.2017.01.023. Epub 2017 Feb 2.

Abstract

We investigated the effect of 4-aminopyridine (4-AP) on experimental autoimmune neuritis (EAN) using a 4-AP-treated group in which 4-AP was administered in the diet, and a control group (n=10 per group). Electrophysiological and pathological assessment was performed in the sciatic nerve. The EAN clinical scores were significantly lower in the 4-AP-treated group than in the control group (p<0.05). The motor conductance velocity two weeks post-immunization was significantly higher in the 4-AP-treated group (p<0.05). Finally, 4-AP did not lead to pathological changes. Thus, 4-AP might be a potential therapeutic agent in demyelinating neuropathy.

Keywords: 4-Aminopyridine; Experimental autoimmune neuritis; Guillain-Barré syndrome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-Aminopyridine / pharmacology
  • 4-Aminopyridine / therapeutic use*
  • Animals
  • Disease Models, Animal
  • Electromyography
  • Evoked Potentials, Motor / drug effects
  • Evoked Potentials, Motor / physiology
  • Freund's Adjuvant / toxicity
  • Male
  • Myelin Proteins / toxicity
  • Neural Conduction / drug effects
  • Neuritis, Autoimmune, Experimental / chemically induced
  • Neuritis, Autoimmune, Experimental / drug therapy*
  • Neuritis, Autoimmune, Experimental / immunology
  • Potassium Channel Blockers / pharmacology
  • Potassium Channel Blockers / therapeutic use*
  • Rats
  • Rats, Inbred Lew
  • Statistics, Nonparametric
  • Vaccination / adverse effects

Substances

  • Myelin Proteins
  • P2 peptide
  • Potassium Channel Blockers
  • Freund's Adjuvant
  • 4-Aminopyridine